INTRODUCTION

Rheumatoid arthritis (RA) is a chronic, systemic, and inflammatory autoimmune disease characterized by persistent synovitis.\(^1\) It can cumulatively cause damage to various tissues such as cartilage, ligaments, and tendons and eventually lead to joint deformities and dysfunction that seriously affect quality of life. The incidence of RA worldwide is approximately 0.5%-1%.\(^2\) The pathogenesis of RA is attributable to both genetic and environmental factors. Susceptible populations with high risks may be affected by both epigenetic marks and environmental exposures, leading to the subsequent cascade of events that are manifested by synovitis and joint destruction and also damages the tissues and organs outside the joint, such as the skin, lungs, eyes, and cardiovascular system.\(^3\) The impact of environmental factors on genetically susceptible individuals is of great significance in the onset and development of RA. Studies have shown that many environmental factors including smoking, hormones, infections, and microbiota are the key factors that lead to the development of RA in genetically susceptible individuals.\(^4-6\) To reduce the disability rate of patients and improve their quality of life, effective biological markers and therapeutic targets for clinical diagnosis and treatment of RA are urgently needed. Therefore, it is necessary to discuss the molecular mechanisms and potential markers of RA.

1.1 | Non-coding RNA

Facilitated by the rapid progress of bioinformatics, the role of RNA in gene regulation has been gradually identified. Before 1990, non-coding RNA (ncRNA) was neglected because that it is unable to encode proteins. However, as reports of functional ncRNA grew, our understanding of the regulation of gene expression has been renewed. Now,
it is widely accepted that mammalian ncRNA constitutes most of the transcripts in the genome. Studies have shown that most DNA in the human genome can be transcribed into RNA. Only about 1.5% of transcripts are translated into proteins, and the remaining up to 90% of non-coding transcripts have no coding function or very low coding capacity. It has also been speculated that the complexity of the organism may come from the difference in non-coding transcripts between higher and lower animals. Many non-coding transcripts are processed into small non-coding RNAs such as lncRNA and miRNA. The feature that ncRNA can interact with DNA, RNA, and protein makes it a key regulator of gene expression under physiological or pathological conditions. According to the size and length of nucleotides, ncRNAs are currently divided into two categories. The first one is small ncRNAs, which includes RNAs that are <200 bp in length, such as rRNA, tRNA, and miRNA. Another one includes lncRNAs, which are transcripts that are non-coding RNA loci with a length of more than 200 bp. A great deal of sequencing studies have shown that lncRNA is preferentially expressed in a tissue-specific pattern, and there is great hope for it to be a therapeutic target for diseases. Interestingly, a regulatory network between lncRNA and miRNA has recently been discovered that may contribute to the study of the pathogenesis of RA.

2 | lncRNA

2.1 | Overview

lncRNAs are a class of ncRNA molecules that do not have protein-coding potential that are ubiquitous in the process of transcription regulation, gene mutation, etc. The abnormal regulation of lncRNAs is correlated with many human diseases. Basically, lncRNAs can be divided into five categories based on their positional relationship to neighboring protein-coding genes: (a) sense lncRNA, which is transcribed from the sense strand of the coding strand; (b) antisense lncRNA, which is a natural antisense transcription product composed of the coding strand transcribed from the antisense strand; (c) bidirectional lncRNA, the expression of it and a neighboring coding transcript on the opposite strand is initiated in close genomic proximity; (d) intergenic lncRNA that is separated by an intron; and (e) intronic lncRNA, which is derived from the intron of a second transcript.

2.2 | Biological functions

lncRNAs are generally considered to have no protein-coding potential. They have significant similarities to classic mRNA, which is also transcribed throughout the genome and translated by RNA polymerase II but can be spliced by polyadenylation occasionally. lncRNAs play an important role in regulating a series of cell transformation processes. For example, lncRNA-p21 modulates the Warburg effect by inhibiting the p53 transcription pathway, and lncRNA-DC regulates dendritic cell differentiation by binding to STAT3. lncRNAs can also regulate gene expression through a variety of mechanisms to show its extensive biological effects. For instance, they served as molecular sponges to regulate gene expression at the post-transcriptional level. In recent years, evidence has indicated that the abnormal expression or mutation of lncRNAs is related to the etiology of a series of human diseases such as tumors, diabetes, and cardiovascular disease. Although recent studies have confirmed that lncRNAs are involved in some autoimmune diseases, its role in the pathogenesis of RA is not yet clear.

3 | miRNA

3.1 | Overview

Another type of ncRNA is miRNA, a class of short RNA molecules of about 21-25 nucleotides in size that is ubiquitous in eukaryotic cells and regulates post-transcriptional silencing of target genes. Compared with protein-encoding genes and mRNA, it is relatively difficult to detect comprehensive association signals of miRNAs, because the genomic region that encodes miRNAs is relatively small. Therefore, to unravel the biological effects of miRNA, we should refocus on miRNA and its target genes in relation to the tissue-specific environment. With the advent of high-throughput sequencing technology in recent years, integrated expression atlas of miRNAs has been established, indicating that miRNA expression levels vary greatly from organization to organization.

3.2 | Biological functions

Investigations have shown that miRNA is pivotal in the pathogenesis of various human diseases. There is overwhelming evidence that miRNAs are regulators of the inflammatory response, some of which are associated with inflammatory diseases such as osteoarthritis (OA) and RA. Qu et al found that miR-194 inhibits the activation of the TGF-β/SMAD pathway, thereby mitigating inflammation in chronic idiopathic urticaria. Xia et al reported that miR-217 and miR-543 are associated with the SIRT1/AMPK/NF-κB pathway, and downregulation of these two miRNAs alleviates the inflammatory response in children with viral myocarditis. As for RA, it is generally believed that miRNAs mediate synovial inflammation and proliferation. Zheng et al used miR-192-5p-overexpressed exosomes to treat rats with RA and found that miR-192-5p can delay the inflammatory response in RA.

4 | INTERACTION BETWEEN lncRNA AND miRNA

4.1 | lncRNA regulates miRNA

Dey et al proclaimed that lncRNA H19 has been involved in the regeneration and differentiation of skeletal muscle. Downregulation
of H19 RNA in myoblast cells and H19 knockout mouse satellite cells impedes skeletal muscle differentiation. Liang et al. uncovered that LINCO0355, a lncRNA, downregulates miR-195, thus promoting cell proliferation and inhibiting the apoptosis of lung adenocarcinoma.

4.2 Regulation of IncRNA by miRNA

Braconi et al. demonstrated that the expression of methyltransferase hinges on the regulation of miRNA-29a, and methyltransferase has been shown to regulate the expression of tumor suppressor IncRNA MEG3 in liver cancer. They speculated that a decrease in MEG3 expression in liver cancer may be because of the regulation of methyltransferase by miRNA-29a to silence MEG3 expression. This hypothesis was confirmed in their subsequent experiments. Compared with wild-type controls, the level of GTL2, the murine homolog of MEG3, was significantly decreased in liver tissues from hepatocyte-specific miR-29a/b1 knockout mice (Table 1).

4.3 IncRNA as a competitive endogenous RNA for miRNA

In 2011, Salmena et al. proposed the competitive endogenous RNA (ceRNA) hypothesis, arguing that ceRNAs can hinder miRNA expression by contending with miRNA. Unlike the conventional theory that RNA was regulated by miRNA, some specific transcripts (ceRNAs) can endogenously compete for miRNA binding, affecting miRNA regulation of the target mRNA, thereby regulating the expression of target genes.

Song et al. identified differentially expressed IncRNAs from the transcriptome sequencing of myoblasts and myotubes and found that Linc-smad7 was upregulated in the early differentiation stage of myoblasts. They found Linc-smad7 overexpression promotes G1 phase myoblast arrest, inhibits DNA replication, and induces myoblast differentiation in vitro. Results of in vivo studies have shown that Linc-smad7 stimulates skeletal muscle regeneration in cardiotoxin-induced muscle damage. Finally, the results of RNA immunoprecipitation analysis and biotin-labeled miR-125b capture showed that Linc-smad7 may compete with miRNA-125b. A recent study indicated that IncRNA WDFY3-AS2 is also a ceRNA that can inhibit ovarian cancer progression by competing with miRNA-18a.

5 RA-RELATED miRNA, IncRNA

5.1 Research progress of IncRNA in RA

A group of IncRNAs was confirmed to be correlated with RA. GAPLINC, also known as a CD44 positive regulator, is a newly discovered functional IncRNA that is expressed in gastric and colorectal cancer. Fibroblast-like synoviocytes (FLS) are the main cell population of synovial cells in patients with RA. They are activated in a chronic inflammatory environment and have certain characteristics which are similar to those of tumor cells. Mo et al. found that the expression of GAPLINC in control group was significantly higher than that of patients with RA, and silencing GAPLINC will increase the level of miR-382-5p and miR-575. Ye et al. analyzed the expression of IncRNA ZFAS1 in patients with RA and found increased expression of ZFAS1 in synovial tissue and FLS in patient with RA, as compared with healthy controls. A functional analysis of RA showed that ZFAS1 silencing inhibits RA-FLS migration and invasion, whereas the overexpression of ZFAS1 has the reverse effect. Further research showed that ZFAS1 directly interacts with miR-27a, thus reducing the expression of miR-27a. This study also

| Name of the IncRNA or miRNA | Interactions and relations with RA |
|-----------------------------|----------------------------------|
| GAPLINC                     | May be involved in the regulation of FLS in RA patients. It interacts with miR-382-5p and miR-575 |
| ZFAS1                       | Downregulating miRNA-27a        |
| HOTAIR                      | HOTAIR has a protective effect in RA. It mainly interacts with miRNA-138 |
| miR-27b                     | Inhibiting HIPK2 expression that would lead to chondrocyte apoptosis |
| miR-101-3p                  | Reducing joint swelling and the rheumatoid factors by downregulating PTGS2 |
| miR-16                      | Highly expressed in the synovial fluid of patients with RA |
| miR-146a                    | Highly expressed in the synovial fluid of patients with RA |
| miR-155                     | Highly expressed in the synovial fluid of patients with RA |
| miR-223                     | Highly expressed in the synovial fluid of patients with RA |
proven that ZFAS1 promotes the migration and invasion of RA-FLS cells through miR-27a, suggesting that ZFAS1 may be an effective therapeutic target for patients with RA. A study by Zhang et al suggested that HOTAIR has a protective effect in RA that is mainly embodied in its regulation of miR-138 expression and NF-κB signaling pathway that promotes proliferation and inhibits inflammation. Their results indicate that HOTAIR may be a promising therapeutic target for RA.

5.2 | Research progress on miRNA in RA

A growing body of research has elaborated on the huge potential of miRNA especially as therapeutic targets and biomarkers in RA. It is well known that the functions of miRNAs in animals include not only regulating cell proliferation, differentiation, and hormone secretion, but also preventing the immune system from developing a disorder. In patients with RA, researchers have found some miRNA molecules related to RA that can regulate certain genes and mitigate inflammation. Zhou et al demonstrated that miR-27b directly inhibits HIPK2 expression that would lead to chondrocyte apoptosis and, thus, ameliorate the development of RA. Recently, Wei et al ascertained that miR-101-3p reduces joint swelling and the rheumatoid factors in rats with RA by downregulating PTGS2, as evidenced by inhibited FLS proliferation and inflammation. Studies have verified that miRNAs are expressed in both the synovial tissue and the circulating blood in patients with RA, meaning that miRNA may serve as a biomarker for RA. Research by Murata et al aimed to explore whether miRNAs are stable in the synovial fluid of patients and whether miRNAs can be used as biomarkers. They found that miR-16, miR-146a, miR-155, and miR-223 are highly expressed in the synovial fluid of patients with RA, while the abundance of these miRNAs is inconsistent in serum and synovial fluid. Singh et al contended that has-miR-132-3p, hasa-miR-146a-5p, and hasa-miR-155-5p are promising biomarkers for predicting the curative effect of methotrexate (MTX) on patients with RA. MTX is a first-line treatment for RA and psoriasis. It has been observed that patients who responded to MTX have a lower expression of those miRNAs, as compared with patients who had no response to the drug.

6 | CONCLUSION

At present, the extensive effects of IncRNA and miRNA have been validated in various human diseases. The abundance of each miRNA and IncRNA will directly influence cellular function and many important physiological functions. Current research is switching to exploit the effect of new ncRNA family members on the pathogenesis of RA. IncRNA and miRNA have been described as promising biomarkers in a wealth of diseases because they are not only expressed in blood circulation, but also stably expressed in stored blood, plasma samples, and even the entire freeze-thaw cycle. However, IncRNAs are scarcely detected because their expression in the nucleus is very low. They are less conserved and susceptible to the environment. Meanwhile, in the entire human genome, IncRNA, with its clear biological function, is only a small part of the large IncRNA family.

In addition, current research on the interaction mechanism between the two molecules in RA is less involved. Based on available research, we summarize major interactions between IncRNA and miRNA in the pathogenesis of RA (Figure 1). It is believed that with the in-depth study of the mechanisms and continuous improvement of expression techniques, IncRNA-miRNA-mRNA interaction is expected to provide new strategies for the clinical diagnosis and targeted treatment of RA.

AUTHOR CONTRIBUTION

Li Sheng contributed as a guarantor of integrity of the entire study. Lei Nie conceptualized the study. Weiwei Liu designed the study and involved in literature research. Xiaodan Mo prepared the manuscript. Weiwei Liu and Li Sheng edited the manuscript. Xiaoyun Wen reviewed the manuscript.

ETHICAL APPROVAL

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

DATA AVAILABILITY STATEMENT

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.
REFERENCES

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-361.
3. Angelotti F, Parma A, Cafaro G, Capocci R, Puxeddu I. One year in review 2017: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):368-378.
4. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin SJ. Smoking and rheumatoid arthritis. Int J Mol Sci. 2014;15(12):22279-22295.
5. Alpizar-Rodriguez D, Finckh A. Environmental factors and hormones in the development of rheumatoid arthritis. Semin Immunopathol. 2017;39(4):461-468.
6. Liu C, Bai B, Skogerbo G, et al. NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res. 2005;33(Database issue):D112-D115.
7. Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Nat Rev Genet. 2012;13(9):629-641.
8. Djebali S, Davis CA, Merkel A, et al. The landscape of transcription in the human genome. Nature. 2012;473(7353):43-51.
9. Ponting CP, Oliver PL, Reik W. Evolution and functions of long non-coding RNAs. Nat Rev Genet. 2008;9(3):208-218.
10. Elgar G, Vavouri T. Tuning in to the signals: noncoding sequences in mammalian genomes. Hum Mol Genet. 2008;17(13):2031-2043.
11. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223-227.
12. Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Int J Mol Sci. 2013;14(9):18790-18808.
13. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775-1789.
14. Li MJ, Zhang J, Liang Q, et al. Exploring genetic associations with eQTL regulation in the human genome. Nucleic Acids Res. 2017;45(10):5653-5665.
15. Tan JY, Marques AC. miRNA-mediated crosstalk between transcripts: the missing "link"? BioEssays. 2016;38(3):295-301.
16. Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14(7):723-730.
17. McPherson R, Pertsinidis A, Kasvlar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488-1491.
18. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155-159.
19. Ponting CP, Oliver PL, Reik W. Evolution and functions of long non-coding RNAs. Cell. 2009;136(4):629-641.
20. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
21. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409-419.
22. Wang P, Yue Y, Han Y, et al. The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. Science. 2014;344(6181):310-313.
23. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298-1307.
24. Wahlestedt C. Targeting long non-coding RNA to therapeutically up-regulate gene expression. Nat Rev Drug Discov. 2013;12(6):433-446.
25. Li G, Liu Y, Meng F, et al. Tanshinone IIA promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by up-regulating IncRNA GASS. Biosci Rep. 2018;38(5):BSR20180626.
26. Archer K, Broskova Z, Bayoumi AS, et al. Long non-coding RNAs as master regulators in cardiovascular diseases. Int J Mol Sci. 2015;16(10):23651-23667.
27. Wu Y, Zhang F, Ma J, et al. Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther. 2015;17:131.
28. Okada Y, Muramatsu T, Suita N, et al. Significant impact of miRNA-target gene networks on genetics of human complex traits. Sci Rep. 2016;6:22223.
29. Lee R, Feinbaum V, Ambros V. A short history of a short RNA. Cell. 2004;116(2 Suppl):S89-S92, 1 p following S6.
30. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862-864.
31. Sakaue S, Hirata J, Maeda Y, et al. Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Res. 2018;46(22):11898-11909.
32. de Rie D. Abeggassai A, Alam T, et al. An integrated expression atlas of microRNAs and their promoters in human and mouse. Nat Biotechnol. 2017;35(9):872-878.
33. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
34. Brest P, Lapuquette P, Soudi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 2011;43(3):242-245.
35. Jones SW, Watkins G, Le Good N, et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage. 2009;17(4):464-472.
36. Yang Y, Huang Q, Luo C, et al. MicroRNAs in acute pancreatitis: from pathogenesis to novel diagnosis and therapy. J Cell Physiol. 2020;235(3):1948-1961.
37. Wu L, Zhang G, Guo C, Zhao X, Shen D, Yang N. MiR-128-3p mediates TNF-alpha-induced inflammatory responses by regulating Sirt1 expression in bone marrow mesenchymal stem cells. Biochem Pharmacol. 2020;252(1):98-105.
38. Smigieleska-Czepiel K, van den Berg A, Jellema P, et al. Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes Immun. 2014;15(2):115-125.
39. Qu S, Yang L, Liu Z. MicroRNA-194 reduces inflammatory response and human dermal microvascular endothelial cells permeability through suppression of TGF-beta/SMAD pathway by inhibiting THBS1 in chronic idiopathic urticaria. J Cell Biochem. 2020;121(1):111-124.
40. Xia K, Zhang Y, Sun D. miR217 and miR543 downregulation mitigates inflammatory response and myocardial injury in children with viral myocarditis by regulating the SIRT1/AMPK/NFkappaB signaling pathway. Int J Mol Med. 2019;45:634-646.
41. Zheng J, Zhu L, Iok In Y, Jia N, Zhu W. Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis. Int Immunopharmacol. 2020;78:105985.
42. Dey BK, Pfeifer K, Dutta A. The H19 long non-coding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev. 2014;28(5):491-501.
43. Liang Y, Rong X, Luo Y, et al. A novel long non-coding RNA LINC00355 promotes proliferation of lung adenocarcinoma cells by down-regulating miR-195 and up-regulating the expression of CCNE1. Cell Signal. 2020;66:109462.
44. Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. *Oncogene*. 2011;30(47):4750-4756.

45. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosseta stone of a hidden RNA language? *Cell*. 2011;146(3):353-358.

46. Song C, Wang J, Ma Y, et al. Linc-smad7 promotes myoblast differentiation and muscle regeneration via sponging miR-125b. *Epigenetics*. 2018;13(6):591-604.

47. Li W, Ma S, Bai X, Pan W, Ai L, Tan W. Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer. *J Cell Physiol*. 2020;235(2):1141-1154.

48. Mo BY, Guo XH, Yang MR, et al. Long non-coding RNA GAPLINC promotes tumor-like biologic behaviors of fibroblast-like synoviocytes as MicroRNA sponging in rheumatoid arthritis patients. *Front Immunol*. 2018;9:702.

49. Ye Y, Gao X, Yang N. LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. *Hum Cell*. 2018;31(1):14-21.

50. Zhang HJ, Wei QF, Wang SJ, et al. LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-kappaB pathway. *Int Immunopharmacol*. 2017;50:283-290.

51. Zhou Y, Li S, Chen P, et al. MicroRNA-27b-3p inhibits apoptosis of chondrocyte in rheumatoid arthritis by targeting HIPK2. *Artif Cells Nanomed Biotechnol*. 2019;47(1):1766-1771.

52. Wei Q, Lv F, Zhang H, et al. MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2. *Biosci Rep*. 2020;40(1):BSR20191136.

53. Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther*. 2010;12(3):R86.

54. Singh A, Patro PS, Aggarwal A. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis. *Clin Rheumatol*. 2019;38(3):877-884.

How to cite this article: Liu W, Sheng L, Nie L, Wen X, Mo X. Functional interaction between long non-coding RNA and microRNA in rheumatoid arthritis. *J Clin Lab Anal*. 2020;34:e23489. [https://doi.org/10.1002/jcla.23489](https://doi.org/10.1002/jcla.23489)